# Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

> **NCT07673107** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 94 (estimated)

## Conditions studied

- Upper Limb Essential Tremor

## Interventions

- **DRUG:** AGN-151607-DP
- **DRUG:** Placebo for AGN-151607-DP

## Key facts

- **NCT ID:** NCT07673107
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-18
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673107, "Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*